Disclosure Plus

ENZYCHEM LIFESCIENCES CORPORATION Receives “Qualified Opinion” on Consolidated and Separate Financial Statements for the First Half of the Year

Limitations on the Scope of Review of Basic Financial Statements and Restrictions on Procedures for Reviewing Subsidiaries

KIM SAE-MI
2026-08-14 23:17:02
ENZYCHEM LIFESCIENCES CORPORATION CI (Photo courtesy of ENZYCHEM LIFESCIENCES CORPORATION)

[Edaily Reporter KIM SAE-MI ] ENZYCHEM LIFESCIENCES CORPORATION(183490)received a “disclaimer of opinion” from its accounting auditor for both its consolidated and separate financial statements for the first half of this year. This marks the second consecutive period—following last year’s disclaimer of opinion on its annual financial statements—in which the company has received a non-conforming opinion.

ENZYCHEM LIFESCIENCES CORPORATION announced on the 14th that it had received a “disclaimer of opinion” from Ichon Accounting Firm regarding its consolidated and separate financial statements for the first half of this year.

The auditor cited the following reasons for the disclaimer of opinion on the separate financial statements: △ limitations on the scope of review of the underlying financial statements; and △ constraints on the review procedures for subsidiaries. For the consolidated financial statements, the auditor also cited limitations on the scope of review of the underlying consolidated financial statements and constraints on the review procedures for subsidiaries.

ENZYCHEM LIFESCIENCES CORPORATION received unqualified opinions for both its consolidated and separate financial statements in the first half of last year, but received a qualified opinion for the 2025 fiscal year due to limitations in the scope of the audit. Issues such as a lack of sufficient audit evidence regarding loan transactions with CookArchive and their accounting treatment, as well as deficiencies in internal controls, were previously raised.

Meanwhile, ENZYCHEM LIFESCIENCES CORPORATION’s first-half consolidated revenue was 38.4 billion won, a 3.4% increase compared to the same period last year. During the same period, operating loss rose 17.2% to 7.3 billion won, while net loss decreased 3.9% to 4.7 billion won.

Economy

Corporation

IT·Science

Economy

[Market In] Turning to Bank Loans Instead of Corporate Bonds… Will Even A-Rated Companies Turn Their Backs on the Bond Market Next Year?

The slump in the non-investment-grade corporate bond market—which has been centered on BBB-rated bonds this year—is expected to spread to A-rated companies next year. As the burden of issuing corporat…
2026-11-14 16:05:05

Corporation

Rookie Baropharm and Embattled Moalife Plus Face Paradoxical Volatility as GC Genome Anchors the Market [K-Bio Pulse]

Amid broader market volatility on Thursday, South Korea’s biopharmaceutical sector lacked a clear directional trend, leaving traditional, profitable pharmaceutical and biotech firms to anchor investor…
2026-11-14 12:47:03

IT·Science

“The Era of 1.5 Million Robots”… The Korean Company JP Morgan Has Singled Out

A forecast indicates that U.S. production of humanoid robots will reach up to 400,000 units by 2030 and 1.5 million units by 2035. Analysts predict that as the humanoid robot industry moves beyond tec…
2026-11-14 08:36:21